Replies to post #112539 on Biotech Values

[jq1234]

The 2-3 mm increase during the first month goes down after anti-hypertension medication is adjusted.

I don't know where they got the 2-3 mm increase during the first month. It is simply not true by deducting from other numbers they provided.

Look at this table, how could it be only 2-3 mm increase before medication adjustment when pre-med and 6-month differences in mean for treatment arms were down 16 and 20 mm while overall mean for all treatment groups still up? The only other possibility was other patients without medication adjustment had significantly higher blood pressure increase. Their explanations didn't add up.

Mean Systolic BP if had Adjustment or Initiation of BP Medication (mmHg)

# Had BP Meds Adjusted/Initiated 11 (7%) 27 (18%) 35 (23%)
BP Measurement
Pre-Adjustment/Initiation 139 149 153
At Month 6 136 128 138
Mean Change -4 -20 -16

I know management made the point before that Roche's Actemra is approved for RA even though it can cause an increase in blood pressure. Not sure if you have any thoughts on that.

Entirely different scope in number of patients involved. R788 is inherently class drug effect.